You are here: Home » Companies » News
Business Standard

Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 bn

Fosun Pharma and Fosun International said following the completion of the acquisition, Gland Pharma has become an indirect non-wholly owned subsidiary of Fosun Pharma and Fosun International

Press Trust of India  |  New Delhi 

Representative image
Representative image

Chinese drug firm has acquired approximately 74 per cent in Hyderabad-based at a valuation of not more than $1.09 billion, the company has said.

Since all the conditions precedent of the of the controlling interest in have been satisfied boards of directors of and Fosun International are pleased to announce that the completion of the of the controlling interest in Gland Pharma, the said in a joint statement.


In the regulatory filing, and Fosun International said following the completion of the acquisition, has become an indirect non-wholly owned subsidiary of and Fosun International.

and Fosun International indirectly hold approximately 74 per cent equity interest in Gland Pharma, the joint statement added.

Fosun Pharmaceutical (Group) Co Ltd had earlier in July last year announced plans to acquire 86.08 per cent stake in for not more than $1.26 billion.

However, the Cabinet Committee on Economic Affairs (CCEA) had raised objections to the proposal earlier this year, a development that came amid heightened tensions between India and China over border dispute.

The Chinese firm on September 17 this year had decided to scale down its proposed in to 74 per cent stake at a valuation of not more than $1.09 billion.

It had said that the "approvals of the relevant PRC authorities in respect of the have been obtained, and the United States anti-trust filings and Indian anti-trust filings have been completed."

"...no review and approval of the India Foreign Investment Promotion Board and the Cabinet Committee on Economic Affairs of India is required in relation to the transactions contemplated under the amendments to the transaction documents under the relevant Indian foreign investment policies," said at that time.

With an increase in the shareholding from the earlier contemplated sale, promoters Ravi Penmetsa and his father P V N Raju will continue on the board of the company had earlier said in a statement.

Besides, the present management team will be in-charge of the day to day running of the company, it had added.

First Published: Wed, October 04 2017. 19:45 IST
RECOMMENDED FOR YOU